Efficacy, safety of biosimilar filgrastim similar to that of filgrastim in daily practice
the ONA take:
The clinical effectiveness and safety of biosimilar filgrastim (Zarxio) in daily clinical practice are similar to that of the originator filgrastim for the prevention of chemotherapy-induced (febrile) neutropenia, according to a new study published online ahead of print in the journal Supportive Care in Cancer.
For the international, prospective, observational, open-label MONITOR-GCSF study, researchers enrolled 1,447 patients with cancer treated with myelosuppressive chemotherapy and receiving prophylaxis with biosimilar filgrastim. Of those, 72.3% received primary prophylaxis and 53.2% initiated prophylaxis between 24 and 72 hours after chemotherapy.
Results showed that 13.2% and 5.9% of patients experienced grade 4 chemotherapy-induced neutropenia and febrile neutropenia, respectively.
Researchers found that 6.1% of patients were hospitalized for (febrile) neutropenia. In regard to safety, 24.7% of patients reported any grade bone pain and 76 patients experienced a total of 148 adverse drug events, of which 4 were serious.
Effectiveness and safety of biosimilar filgrastim (Zarxio) in daily clinical practice are similar to that of the originator filgrastim.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|